Developing,Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events)

Abstract

Background:

In 2013, a randomized, double-blind, active comparator-controlled, event-driven cardiovascular outcomes trial (DEVOTE) was initiated to compare the cardiovascular safety of insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) in patients with type 2 diabetes at high risk of cardiovascular events. The FDA agreed that an interim analysis could form the basis for an early regulatory approval. We report here the operational model developed to support the DEVOTE interim analysis and the results.

Methods:

The interim analysis model was designed to reduce the risk of any confidentiality breaches. The Data Access Management Plan comprehensively described the interim analysis operational processes and procedures to maintain the integrity of the ongoing trial while the interim analysis was conducted, submitted, and acted upon by the FDA, and also until completion of the full trial. Most importantly, those who were unblinded to the interim results were limited to a team of 14 members.

Results:

A total of 150 first major adverse cardiovascular events were recorded at cut-off for the interim analysis. The estimated hazard ratio was 0.92 (95% CI 0.67, 1.27) and non-inferiority to glargine U100 was confirmed as the upper bound of the confidence interval was below 1.8, as prespecified. Based on these results, the FDA approved the use of degludec and degludec/insulin aspart (IDegAsp) in the United States in 2015 before trial completion.

Conclusions:

The DEVOTE interim analysis succeeded as a model by which to conduct an interim analysis and submit confidential data for regulatory review and action while continuing the trial to address a primary hypothesis.

Keywords

Interim analysis cardiovascular outcomes trials data access management plan insulin degludec insulin glargine U100

Get full access to this article

View all access options for this article.

References

Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes: guidance for industry. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Published December 2008.

Schnell

Rydén

Standl

Ceriello

. Current perspectives on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol. 2016;15:139.

FDA Briefing Document. Insulin degludec and insulin degludec/insulin aspart treatment to improve glycemic control in patients with diabetes mellitus briefing document. https://wayback.archive-it.org/7993/20170114010827/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM327017.pdf. Published 2012.

Marso

McGuire

Zinman

. Design of DEVOTE (trial comparing cardiovascular safety of insulin degludec vs insulin glargine in patients with type 2 diabetes at high risk of cardiovascular events)—DEVOTE 1. Am Heart J. 2016;179:175–183.

U.S. Food and Drug Administration (FDA). Confidentiality of interim results in cardiovascular outcome safety trials public hearing. https://www.fda.gov/downloads/Drugs/NewsEvents/UCM436369.pdf. Published August 11, 2014.

Fleming

. Protecting the confidentiality of interim data: addressing current challenges. Clin Trials. 2015;12:5–11.

Marso

McGuire

Zinman

. Comparative safety of insulins: degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377:723–732.

World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–2194.

ICH. ICH Harmonised Tripartite Guideline: guideline for good clinical practice. J Postgrad Med. 2001;47:199–203.

10.

Grant

Altman

Babiker

. Issues in data monitoring and interim analyses of trials. Health Technol Assess. 2005;9:1–238.

11.

Green

Fleming

O’Fallon

. Policies for study monitoring and interim reporting of results. J Clin Oncol. 1987;5:1477–1484.

12.

Nissen

Wolski

Prcela

. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016;315:990–1004.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.43 MB